拉布立酶给药前抢先快速检测G6PD缺乏症的影响:回顾性研究
该回顾性研究在大型学术城市医院2.5年内对260例肿瘤患者在使用拉布立酶前进行G6PD缺乏症半定量生化检测,检出16例G6PD缺乏(6.1%),检测结果平均4小时内电子可得。4例G6PD缺乏患者中2例仍接受拉布立酶并发生溶血,提示需加强医生教育。
要点
- 拉布立酶给药前快速G6PD检测可识别G6PD缺乏患者,结果平均4小时内可得。
- 260例受检者中16例(6.1%)为G6PD缺乏,包括6例女性。
- 4例G6PD缺乏患者中2例仍接受拉布立酶并发生溶血,提示需改善医生教育。
核心结论
- 拉布立酶给药前提供快速G6PD状态信息有助于个体化医疗,但需改善医生教育以避免G6PD缺乏患者仍接受拉布立酶。
研究设计与样本
- 回顾性病历审查,纳入大型学术城市医院2.5年内所有在使用拉布立酶前进行G6PD缺乏症半定量生化检测的肿瘤患者,共260例。
主要发现
- 260例受检者中16例(6.1%)为G6PD缺乏,包括6例女性。
- 检测结果平均在采样后4小时内电子可得,多数结果在2-3小时内可得。
- 4例G6PD缺乏患者出现尿酸水平升高。
- 2例G6PD缺乏患者接受拉布立酶后发生溶血,并得到适当处理。
临床怎么用
- 对计划使用拉布立酶的肿瘤患者,可考虑在给药前进行快速G6PD缺乏症检测以获取G6PD状态。
- 检测结果快速可得(平均4小时内)有助于临床决策,但需结合医生教育确保G6PD缺乏患者避免使用拉布立酶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy in humans, can cause acute haemolysis resulting from exposure to certain medications, chemicals, infections and fava beans. Rasburicase, used to manage elevated uric acid levels in the oncologic emergency of tumour lysis syndrome, is one such drug. The US Food and Drug Administration (FDA) recommends testing of G6PD status prior to rasburicase administration for patients at higher risk for G6PD deficiency. METHODS: We performed a retrospective chart review of all oncology patients for whom a semi-quantitative biochemical test for detecting G6PD deficiency was performed prior to rasburicase administration over a 2.5-year period, in a large academic metropolitan hospital. RESULTS: We identified 16 out of 260 tested individuals as G6PD-deficient (6.1%), including six females. On average, test results were electronically available to health care providers within 4 hours of sample collection, with most results available within 2-3 hours. Four G6PD-deficient patients developed elevated uric acid levels. Two of the G6PD-deficient patients were treated with rasburicase, and subsequently developed haemolysis, which was appropriately managed. CONCLUSION: In summary, by providing information about G6PD status with a rapid turnaround time, we have taken a significant step towards personalized medicine in our institution. In spite of the test implementation, two out of four G6PD-deficient patients, who were no longer candidates for rasburicase use, still received the drug, highlighting the need for improved provider education.
引用
- Ganapathi M, Campbell P, Ofori K, et al. Impact of pre-emptive rapid testing for glucose-6-phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study. Br J Clin Pharmacol. 2022. PMID: 35419830. doi:10.1111/bcp.15353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。